References of "Belgian Journal of Medical Oncology [=BJMO]"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailThe development of a safety culture: a fanciful hope in the health care sector ?
COUCKE, Philippe ULg

in Belgian Journal of Medical Oncology [=BJMO] (2014), 8(3), 66-71

Detailed reference viewed: 15 (3 ULg)
Full Text
Peer Reviewed
See detailOperational Risk Management (ORM): the aviation safety model can be transposed into the medical sector
COUCKE, Philippe ULg; DELGAUDINE, Marie ULg; BOGA, Deniz ULg et al

in Belgian Journal of Medical Oncology [=BJMO] (2013), 7(5), 137-141

Detailed reference viewed: 32 (8 ULg)
Full Text
Peer Reviewed
See detailThe Spectrum hypothesis and the technical revolution in radiotherapy at the origin of major paradigm shift
COUCKE, Philippe ULg

in Belgian Journal of Medical Oncology [=BJMO] (2012), 6(5), 151-156

Detailed reference viewed: 32 (3 ULg)
Full Text
Peer Reviewed
See detailNew indications for radiotherapy: primary liver cancer and secondary liver oligometastases
JANVARY, Zsolt Levente ULg; JANSEN, Nicolas ULg; MARTINIVE, Philippe ULg et al

in Belgian Journal of Medical Oncology [=BJMO] (2011), 5(1), 8-13

Surgery is considered to be the standard treatment for intrahepatic malignancies, primary <br />cancers and metastatic lesions. However, a great many patients are not eligible for surgical <br ... [more ▼]

Surgery is considered to be the standard treatment for intrahepatic malignancies, primary <br />cancers and metastatic lesions. However, a great many patients are not eligible for surgical <br />intervention. Modern stereotactic radiotherapy has the potential to be an effective alternative <br />treatment modality with low toxicity for patients with primary hepatocellular carcinoma <br />and liver oligometastases. In this paper we intend to review the current status and published <br />experiences in the field of liver irradiation. [less ▲]

Detailed reference viewed: 54 (7 ULg)
Full Text
Peer Reviewed
See detailAccelerated partial breast irradiation: state of the art
COUCKE, Philippe ULg; JANSEN, Nicolas ULg; JANVARY, Zsolt Levente ULg et al

in Belgian Journal of Medical Oncology [=BJMO] (2011), 5(1), 3-7

Accelerated partial breast irradiation can be applied by means of different techniques. It <br />offers an opportunity for reducing the treatment duration considerably and harbours the <br />potential for ... [more ▼]

Accelerated partial breast irradiation can be applied by means of different techniques. It <br />offers an opportunity for reducing the treatment duration considerably and harbours the <br />potential for less exposure of healthy tissue to higher radiation doses. However, evidence <br />issued from randomized trials is limited. European and American experts call our attention <br />to the potential dangers of widespread implementation of these techniques without any <br />long-term data on outcome and ask for complete information of patients on the potential <br />hazards and risks if accelerated partial breast irradiation is used instead of whole breast <br />irradiation. [less ▲]

Detailed reference viewed: 55 (8 ULg)
Full Text
Peer Reviewed
See detailCross talk between dendritic and natural killer cells in the presence of vaccine agent against cervical cancer
Langers, Inge ULg; Renoux, Virginie ULg; Reschner, Anca ULg et al

in Belgian Journal of Medical Oncology [=BJMO] (2010, January 30), 4

Detailed reference viewed: 61 (24 ULg)
Full Text
Peer Reviewed
See detailPractice guidelines on the use of erythropoiesis-stimulating agents in the treatment of chemotherapy-induced anemia
Dirix, L.; Awada, A.; Bron, D. et al

in Belgian Journal of Medical Oncology [=BJMO] (2010), 4

On July 1st 2009, a panel of experts met with the goal to provide a joint medical opinion on the use of erythropoiesis-stimulating agents (ESAs) in chemotherapy-induced anemia (CIA), as well as a joint ... [more ▼]

On July 1st 2009, a panel of experts met with the goal to provide a joint medical opinion on the use of erythropoiesis-stimulating agents (ESAs) in chemotherapy-induced anemia (CIA), as well as a joint proposal for revised reimbursement criteria in Belgium. The goal is to provide a clear and workable guidance on the use of ESAs in their registrered indication : chemotherapy induced anemia in cancer patients. An overview of participating experts can be found in Table 1. [less ▲]

Detailed reference viewed: 56 (2 ULg)
Full Text
Peer Reviewed
See detailHematopoietic stem cell transplantation in the treatment strategy of acute leukemia
Baron, Frédéric ULg; Beguin, Yves ULg

in Belgian Journal of Medical Oncology [=BJMO] (2010), 4

This review article discusses the current indications for allogeneic hematopoietic stem cell transplantation in adult patients with acute myeloid or lymphoblastic leukemia

Detailed reference viewed: 32 (6 ULg)
Full Text
Peer Reviewed
See detailA phase I trial of sutent, a tyrosine kinase inhibitor combined with ionizing irradiation in rectal cancer: protocol KIRC 08-01
COUCKE, Philippe ULg

in Belgian Journal of Medical Oncology [=BJMO] (2010), 4(2), 65-66

Detailed reference viewed: 15 (7 ULg)
Full Text
Peer Reviewed
See detailA phase I trial of sunitinib, a tyrosine kinase inhibitor (TKI) combined with ionizing irradiation in rectal cancer
Coucke, Philippe ULg

in Belgian Journal of Medical Oncology [=BJMO] (2009), 3(3), 117

Detailed reference viewed: 13 (2 ULg)
Full Text
Peer Reviewed
See detailTumor Margin after conservative breast cancer surgery for early disease: an issue or not ?
Coucke, Philippe ULg; Vavassis, Peter; Vanderick, JEAN ULg et al

in Belgian Journal of Medical Oncology [=BJMO] (2009), 3(3), 93-100

Summary is standard of care. However, the question is Conservative breast surgery (CBS), i.e. tumorec- whether this approach is able to consolidate local tomy (TUM), has replaced more radical surgical ... [more ▼]

Summary is standard of care. However, the question is Conservative breast surgery (CBS), i.e. tumorec- whether this approach is able to consolidate local tomy (TUM), has replaced more radical surgical control irrespective of the extent of the surgical approaches such as mastectomy (MAST) and margin. No consensus exists in the literature con-quadrantectomy (QUAD). The aim of surgeons is cerning what should be considered as a minimal to avoid recurrence and still obtain a good cos-and hence a safe margin. This review will summetic result. After CBS for early disease, adjuvant marize the published data in order to try to define radiation consisting of whole breast irradiation a pragmatic treatment approach. followed by a boost dose on the surgical bed is standard of care. However, the question is whether this approach is able to consolidate local control irrespective of the extent of the surgical margin. No consensus exists in the literature concerning what should be considered as a minimal and hence a safe margin. This review will summarize the published data in order to try to define a pragmatic treatment approach. [less ▲]

Detailed reference viewed: 50 (4 ULg)
Full Text
Peer Reviewed
See detailA dosimetric study comparing breast radiotherapy planned in the prone versus supine positions and via conformal 3D versus IMRT techniques
Coucke, Philippe ULg

in Belgian Journal of Medical Oncology [=BJMO] (2009), 3(3), 117

Detailed reference viewed: 10 (1 ULg)
Full Text
Peer Reviewed
See detailIs an evidence-based approach unrealistic in NSCLC?
Coucke, Philippe ULg; Barthelemy, Nicole ULg; Bosquee, Léon ULg et al

in Belgian Journal of Medical Oncology [=BJMO] (2008), volume 2(6), 326-333

Summary Non-small cell lung cancer (NSCLC) is a heterogeneous tumour. A wide variety of treatment options is currently available. Surgery remains the mainstay of curative treatment and an operative ... [more ▼]

Summary Non-small cell lung cancer (NSCLC) is a heterogeneous tumour. A wide variety of treatment options is currently available. Surgery remains the mainstay of curative treatment and an operative approach will be selected in function of disease stage, tumour resectability and performance status of the patient. Adjuvant chemotherapy is considered standard at least for stage II and III disease. In stage III disease, resectability should be decided in function of the cytological/histological confirmation of N2 disease. If N2-disease cannot be highlighted at work-up, the patients are submitted to surgery followed by adjuvant chemotherapy. If patients are staged pN0-pN1 after surgery, ostoperative radiotherapy should not be given. However, if pN2 is discovered at surgery, there might be a place for postoperative radiotherapy but this still needs confirmation. In case of cytological/histological confirmation of pN2 disease prior to surgery, patients should not be operated but treated with a combination of oncomitant chemoradiotherapy. This treatment algorithm will be evaluated by reviewing the published evidence issued from randomized controlled trials. [less ▲]

Detailed reference viewed: 39 (11 ULg)
Full Text
Peer Reviewed
See detailRisk adaptive treatment in Hodgkin's lympoma: reduction of radiation dose and irradiated volume
Coucke, Philippe ULg; Barthelemy, Nicole ULg; Hustinx, Roland ULg et al

in Belgian Journal of Medical Oncology [=BJMO] (2008), 2(2), 85-97

Treatment–related late complications on nontarget normal tissues and appearance of secondary malignancies are well known side-effects induced by effective treatment regimens currently used in the curative ... [more ▼]

Treatment–related late complications on nontarget normal tissues and appearance of secondary malignancies are well known side-effects induced by effective treatment regimens currently used in the curative approach of early and advanced Hodgkin’s lymphoma. Radiotherapy (RT) and chemotherapy (CT) can lead to these late complications. Efforts have been conducted to reduce the morbidity and mortality related to these treatments. In particular there has been a progressive shift from radiotherapy used as sole modality to chemotherapy as first line followed by consolidation radiotherapy. As the side-effects of radiotherapy are linked to dose, volume and interaction with chemotherapy, trials have been launched to assess the impact of modifying the characteristics of the radiation treatment. For early-stage Hodgkin’s lymphoma radiotherapy cannot be avoided but dose and volume can be reduced. In advanced Hodgkin’s lymphoma omitting radiotherapy seems reasonable only in case of complete response (CR). The clinical trials allowing such a paradigm shift are highlighted in this review. [less ▲]

Detailed reference viewed: 57 (14 ULg)